Company / Current Liabilities
NovaBay Pharmaceuticals, Inc. Current Liabilities History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$2.8M
FY2024
5-year range
$2.8M / $4.3M
FY2020-FY2024
Trend
-33.5%
vs FY2023
Sector context
#214 of 215
Health Care
What the data says
Among 215 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the top 0% for current liabilities. Current Liabilities has fluctuated over the past 10 years, ranging from $3M in FY2020 to $6M in FY2019.
Based on SEC 10-K filings.
$3M in FY2024 with a 5-year CAGR of -12.9%.
Improved from $4M to $3M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -6.2%
- 5-Year CAGR
- -12.9%
- 10-Year CAGR
- -
Sector benchmark
Top 0% in Health CareTop 0% of 215This company $2.8M Sector average $1.6B
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -12.9%, indicating a declining trend.
- In FY2024, current liabilities decreased 33.5% year-over-year.
- Ranks #214 out of 215 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.8M | -33.5% |
| FY2023 | $4.3M | +0.5% |
| FY2022 | $4.3M | +23.7% |
| FY2021 | $3.4M | +21.5% |
| FY2020 | $2.8M | -50.2% |
| FY2019 | $5.7M | +47.8% |
| FY2018 | $3.8M | -22.7% |
| FY2017 | $5.0M | +15.2% |
| FY2016 | $4.3M | -6.7% |
| FY2015 | $4.6M | +38.5% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026